MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
| Weiss Ratings | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.18 | |||
| Price History | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.06% | |||
| 30-Day Total Return | -16.73% | |||
| 60-Day Total Return | -8.59% | |||
| 90-Day Total Return | 21.88% | |||
| Year to Date Total Return | -16.73% | |||
| 1-Year Total Return | -37.24% | |||
| 2-Year Total Return | -57.31% | |||
| 3-Year Total Return | -62.29% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -53.95% | |||
| 52-Week Low % Change | 91.88% | |||
| Price | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.00 | |||
| 52-Week Low Price | $4.56 | |||
| 52-Week Low Price (Date) | Jan 28, 2025 | |||
| 52-Week High Price (Date) | Apr 05, 2024 | |||
| Valuation | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 34.71M | |||
| Enterprise Value | 35.05M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.53 | |||
| Earnings Per Share Growth | -46.19% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -1.77 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $8.41 | |||
| Enterprise Value/EBITDA (TTM) | -2.76 | |||
| Enterprise Value/EBIT | -2.70 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 3.96M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 212 994 8250 | |||
| Address | 149 Fifth Avenue New York, NY 10010 | |||
| Website | minktherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -157.98% | |||
| Return on Equity | -- | |||
| Income Statement | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -12.71M | |||
| EBIT (TTM) | -12.98M | |||
| Net Income (TTM) | -10.78M | |||
| Net Income Avl. to Common (TTM) | -10.78M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 54.88% | |||
| EPS Diluted (TTM) | -3.53 | |||
| EPS Diluted Growth (Q YOY) | 21.07% | |||
| Balance Sheet | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.58M | |||
| Cash Per Share (Q) | $1.16 | |||
| Total Current Assets (Q) | 4.99M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -19.59M | |||
| Current Ratio (Q) | 0.717 | |||
| Book Value Per Share (Q) | -$4.94 | |||
| Total Assets (Q) | 5.72M | |||
| Total Current Liabilities (Q) | 6.96M | |||
| Total Debt (Q) | 4.92M | |||
| Total Liabilities (Q) | 25.31M | |||
| Total Common Equity (Q) | -19.59M | |||
| Cash Flow | INKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 10.82M | |||
| Net Change in Cash (TTM) | 1.21M | |||
| Levered Free Cash Flow (TTM) | -12.68M | |||
| Cash from Operations (TTM) | -9.56M | |||
